NDUFA12 Gene

Migration, Crosslink

📖

NDUFA12 Gene

active

wiki page Created: 2026-04-02T07:19:33 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ndufa12

📖 Wiki Page

gene2177 wordssynced 2026-04-02

NDUFA12 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NDUFA12 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NDUFA12</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NDUFA12</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=NDUFA12" target="_blank">Search NCBI</a></td>
</tr>
</table>

NDUFA12 Gene

Introduction

...

NDUFA12 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NDUFA12 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NDUFA12</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NDUFA12</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=NDUFA12" target="_blank">Search NCBI</a></td>
</tr>
</table>

NDUFA12 Gene

Introduction

Mermaid diagram (expand to render)

NDUFA12 (also known as B17.2 or NADH dehydrogenase (ubiquinone) subunit A12) is a nuclear-encoded mitochondrial gene that encodes an accessory subunit of NADH:ubiquinone oxidoreductase, also known as Complex I of the mitochondrial respiratory chain["@giant2015"][@atomic2016]. Complex I is the largest enzyme in the mitochondrial electron transport chain, comprising over 40 subunits organized into hydrophobic membrane arms and hydrophilic peripheral arms["@assembly2017"]. NDUFA12 is a supernumerary subunit that, while not essential for the core catalytic function, plays important roles in the assembly, stability, and regulation of the complex["@novel2009"][@mitochondrial2015].

NDUFA12 has garnered significant research interest due to its involvement in mitochondrial complex I deficiency, one of the most common respiratory chain defects in humans["@complex2012"]. Mutations in NDUFA12 and other Complex I subunits lead to severe neurodegenerative conditions including Leigh syndrome, a devastating early-onset metabolic disorder characterized by bilateral brainstem and basal ganglia lesions["@leigh2010"][@leigh2014].

Gene Structure and Chromosomal Location

The NDUFA12 gene is located on chromosome 12q14.2, a region that has been implicated in various neurological disorders[@mitochondrial2015]. The gene encodes a protein of 172 amino acids that is synthesized in the cytoplasm and imported into mitochondria via the TOM/TIM translocase system[@assembly2017].

Gene Organization

Gene Symbol: NDUFA12
NCBI Gene ID: 4706
OMIM: 614225
Ensembl ID: ENSG00000184752
UniProt: Q9P0J7

The protein localizes to the mitochondrial matrix-facing side of Complex I, particularly in the ND2 module of the membrane arm[@atomic2016]. As a supernumerary subunit, NDUFA12 is not part of the minimal core required for catalytic activity but contributes to the structural integrity and functional regulation of the holoenzyme.

Protein Structure and Function

Structural Organization

NDUFA12 adopts a small globular fold that interacts with surrounding core subunits to stabilize the complex[@atomic2016]. Cryo-electron microscopy studies have resolved the atomic structure of mammalian Complex I, revealing the precise positioning of NDUFA12 within the ND2 module of the membrane arm. The protein contributes to the proper conformation of the complex, particularly in the region connecting the peripheral and membrane arms.

Role in Oxidative Phosphorylation

Complex I catalyzes the oxidation of NADH and the transfer of electrons to ubiquinone, coupled with the translocation of four protons across the mitochondrial inner membrane[@giant2015]. This creates the electrochemical gradient that drives ATP synthesis through ATP synthase. NDUFA12 contributes to this process through several mechanisms:

Structural Stabilization: The subunit helps maintain the proper conformation of the complex[@assembly2017].

Assembly Facilitation: NDUFA12 participates in the stepwise assembly of Complex I from individual subunits and assembly intermediates[@identification2008][@novel2009].

Regulatory Modulation: The subunit may play a role in modulating the activity of Complex I in response to cellular energy demands.

Mitochondrial Dynamics

Mitochondria are dynamic organelles that undergo continuous fusion and fission to maintain cellular homeostasis[@bioenergetics2020]. The proper function of Complex I, including accessory subunits like NDUFA12, is essential for mitochondrial membrane potential maintenance and cellular bioenergetics. Dysfunction of Complex I can lead to fragmented mitochondrial networks and impaired cellular respiration[@bioenergetics2018].

Role in Neurodegenerative Diseases

Mitochondrial Complex I Deficiency

Mitochondrial complex I deficiency is one of the most common respiratory chain defects in humans, accounting for approximately 30% of all mitochondrial disease cases[@mitochondrial2015]. This deficiency can result from mutations in any of the over 40 Complex I subunits or in assembly factors that facilitate the proper assembly of the complex. NDUFA12 mutations, while rare, have been documented as a cause of isolated complex I deficiency[@complex2012][@complex2019].

The clinical manifestations of Complex I deficiency are highly variable and include:

Leigh Syndrome: A severe neurodegenerative disorder characterized by bilateral brainstem and basal ganglia lesions, leading to developmental regression, motor abnormalities, and typically early mortality[@leigh2010].
Leigh-like Syndrome: A phenotype resembling Leigh syndrome but with atypical features or less severe presentation.
Mitochondrial Encephalomyopathy: A broader term for neurological syndromes associated with mitochondrial dysfunction.
Cardiomyopathy: Some patients present with hypertrophic or dilated cardiomyopathy.

Biochemically, Complex I deficiency leads to impaired NADH oxidation, reduced ATP production, and increased reactive oxygen species (ROS) generation[@oxidative2014]. The resulting energy crisis particularly affects high-energy-demand tissues, including the brain, heart, and skeletal muscle.

Alzheimer's Disease

Emerging evidence suggests that mitochondrial dysfunction, including Complex I impairment, plays a significant role in the pathogenesis of Alzheimer's disease (AD)[@oxidative2014][@brain2014][@ad2021]. While NDUFA12 has not been directly implicated in AD causation, several lines of evidence connect Complex I dysfunction to AD pathology:

Oxidative Stress: Complex I deficiency leads to increased reactive oxygen species (ROS) production, contributing to the oxidative damage observed in AD brains[@oxidative2014].

Amyloid-beta Effects: Amyloid-beta peptides have been shown to directly inhibit mitochondrial respiratory chain complexes, including Complex I[@ad2021].

Tau Pathology: Mitochondrial dysfunction can exacerbate tau hyperphosphorylation and neurofibrillary tangle formation.

NAD+ Metabolism: Complex I dysfunction reduces cellular NAD+ levels, which are critical for sirtuin activity and cellular stress responses[@nadh2019][@nad2020].

Mitochondrial Dynamics: AD is associated with altered mitochondrial dynamics, including fission and fusion abnormalities that affect Complex I function[@bioenergetics2018].

Parkinson's Disease

Parkinson's disease (PD) is particularly linked to mitochondrial dysfunction due to the selective vulnerability of dopaminergic neurons in the substantia nigra[@pd2020]. While the primary mitochondrial defects in PD involve Complex I in the substantia nigra, the broader role of Complex I subunits including NDUFA12 is relevant:

Complex I Inhibition: Rotenone and MPTP, toxins that induce PD-like pathology, specifically inhibit Complex I.

Alpha-synuclein Interaction: Mitochondrial dysfunction can promote alpha-synuclein aggregation, and vice versa, creating a vicious cycle[@mitophagy2021].

Dopaminergic Neuron Vulnerability: The high energy demands of dopaminergic neurons make them particularly susceptible to Complex I impairment.

PINK1/Parkin Pathway: Mitochondrial dysfunction activates mitophagy pathways involving PINK1 and Parkin, which may be affected by Complex I activity[@mitophagy2021].

Prevalence: Studies have shown an increased prevalence of mitochondrial disease in PD patients, suggesting shared pathogenic mechanisms[@pd2020].

Other Neurodegenerative Conditions

Complex I dysfunction has been implicated in numerous other neurodegenerative conditions:

Huntington's Disease: Mitochondrial deficits are a hallmark of HD pathology, with Complex I impairment contributing to neurodegeneration.
Amyotrophic Lateral Sclerosis (ALS): Energy metabolism abnormalities contribute to motor neuron degeneration[@neuro2021].
Multiple Sclerosis: Mitochondrial dysfunction in oligodendrocytes contributes to demyelination.
Friedreich's Ataxia: Primary mitochondrial dysfunction involving iron-sulfur cluster metabolism affects Complex I function.

Brain Expression Pattern

NDUFA12 is expressed in most human tissues, with particularly high levels in tissues with high energy requirements[@brain2008]:

Brain: Prominent expression in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and cerebellar Purkinje cells. Neurons exhibit particularly high expression due to their substantial energy demands for synaptic transmission and action potential propagation[@neuro2021].
Heart: High expression in cardiac muscle, where continuous energy supply is essential for contractile function.
Skeletal Muscle: Abundant in muscle fibers, particularly in type I (slow-twitch) fibers with high mitochondrial density.
Kidney: Significant expression in renal tubular cells with high metabolic activity.

Within the brain, NDUFA12 expression is particularly notable in neurons, where mitochondrial density is high to support sustained energy demands. Glial cells also express NDUFA12, though at lower levels than neurons.

Clinical Genetics

Inheritance Pattern

Mitochondrial complex I deficiency follows multiple inheritance patterns:

Autosomal Recessive: For nuclear-encoded Complex I subunits like NDUFA12, inheritance follows autosomal recessive patterns[@therapeutic2018]. Biallelic mutations in NDUFA12 can cause isolated Complex I deficiency.
Mitochondrial: Some Complex I deficiencies result from mutations in the mitochondrial genome.
Sporadic: De novo mutations can occur, leading to isolated cases without family history.

Diagnosis

Diagnostic approaches for suspected NDUFA12-related mitochondrial disease include:

Biochemical Testing: Measurement of Complex I activity in muscle biopsy or skin fibroblasts[@mitochondrial2009].

Genetic Testing: Targeted panel testing or whole-exome sequencing for NDUFA12 mutations[@complex2019].

Neuroimaging: MRI findings characteristic of Leigh syndrome or other mitochondrial encephalopathies[@leigh2014].

Metabolic Markers: Elevated lactate in blood and cerebrospinal fluid.

Genetic Variants

While pathogenic variants in NDUFA12 are less common than in some other Complex I subunits, several disease-causing mutations have been reported in the literature[@complex2012][@assembly2018]. The spectrum of variants includes:

Missense mutations: Affecting protein folding or stability
Splice-site mutations: Leading to exon skipping
Nonsense mutations: Resulting in truncated proteins

Therapeutic Approaches

Current Treatment Strategies

There is currently no cure for mitochondrial Complex I deficiency, but several therapeutic approaches are under investigation[@therapeutic2018][@translation2022]:

Cofactor Supplementation:

L-arginine and L-carnitine to support mitochondrial function
Coenzyme Q10 (CoQ10) as an electron carrier
B vitamins for metabolic support

Dietary Interventions:

Ketogenic diet in some seizure disorders
Pyruvate supplementation to bypass Complex I

NAD+ Precursors:

Nicotinamide riboside (NR) to boost NAD+ levels[@nad2020]
NMN (nicotinamide mononucleotide) supplementation

Mitochondrial Chaperones: Pharmacological enhancement of mitochondrial protein quality control[@mitochaperone2021].

Emerging Therapies

Gene Therapy: AAV-mediated gene delivery for nuclear-encoded mitochondrial genes[@crispr2022].

Small Molecule Modulators: Compounds that enhance Complex I assembly or stability.

Mitochondrial Replacement Therapy: Novel approaches to replace defective mitochondria.

Stem Cell Therapy: Induced pluripotent stem cells (iPSC) for disease modeling and potential therapy[@crispr2022].

CRISPR-Based Approaches: Gene editing strategies to correct pathogenic mutations[@crispr2022].

Animal Models

Several animal models have been developed to study Complex I deficiency and NDUFA12 function:

Knockout Mice: NDUFA12 knockout mice show embryonic or early postnatal lethality, highlighting the essential nature of Complex I.
Zebrafish Models: Zebrafish provide a tractable system for studying mitochondrial development and neural pathology.
Drosophila: Fruit fly models allow genetic dissection of Complex I function.
Patient-Derived iPSCs: Induced pluripotent stem cells from patients with Complex I mutations provide human disease models[@crispr2022].

These models have revealed that Complex I deficiency leads to developmental abnormalities, movement disorders, and premature death, recapitulating key features of human mitochondrial disease.

Research Directions

Current research on NDUFA12 and Complex I in neurodegeneration focuses on several key areas:

Structural Studies: High-resolution cryo-EM structures to understand subunit interactions and assembly mechanisms[@atomic2016].

Assembly Mechanisms: Elucidating the stepwise pathway of Complex I biogenesis, including the role of assembly factors like NDUFAF2 and NDUFAF6[@identification2008][@novel2009].

Disease Modeling: iPSC-derived neurons from patients with Complex I mutations provide insights into disease mechanisms and therapeutic screening[@crispr2022].

Biomarkers: Development of blood and CSF biomarkers for disease monitoring and treatment response.

Therapeutic Screening: High-throughput screens for compounds that enhance Complex I activity or assembly.

Interconnectivity: Understanding how Complex I dysfunction interacts with other cellular pathways, including mitophagy, neuroinflammation, and metabolic regulation[@mitophagy2021][@mitochaperone2021].

References

[: Sazanov LA, A giant molecular proton pump: structure and mechanism of respiratory complex I (2015)](https://pubmed.ncbi.nlm.nih.gov/25991374/)

[: Fiedorczuk K, et al, Atomic structure of the entire mammalian mitochondrial complex I (2016)](https://pubmed.ncbi.nlm.nih.gov/27505352/)

[: Galkin A, et al, Identification of the mitochondrial NDUFAF2 as the complex I assembly factor (2008)](https://pubmed.ncbi.nlm.nih.gov/18342227/)

[: Lazarou M, et al, Novel mitochondrial complex I assembly factors (2009)](https://pubmed.ncbi.nlm.nih.gov/19490921/)

[: Koopman WJ, et al, Mitochondrial complex I deficiency and neurological disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25664952/)

[: Guerrero-Castillo S, et al, The assembly pathway of mitochondrial respiratory chain complex I (2017)](https://pubmed.ncbi.nlm.nih.gov/28218918/)

[: Antonicka H, et al, Mutations in COX10 result in a defect in mitochondrial heme A biosynthesis and cause complex IV deficiency (2003)](https://pubmed.ncbi.nlm.nih.gov/12707853/)

[: Janssen RJ, et al, Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19293253/)

[: Papa S, et al, Mitochondrial respiratory chain diseases and the brain (2008)](https://pubmed.ncbi.nlm.nih.gov/18776757/)

[: Johri A, et al, Oxidative stress and mitochondrial dysfunction in neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/24823302/)

[: Finsterer J, Leigh and Leigh-like syndrome in children (2010)](https://pubmed.ncbi.nlm.nih.gov/20052714/)

[: Liu L, et al, NAD+ metabolism: a promising therapeutic target for neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31154718/)

[: Mimaki M, et al, Complex I deficiency: clinical features, biochemistry and molecular biology (2012)](https://pubmed.ncbi.nlm.nih.gov/22461335/)

[: Formosa LE, et al, Insights into the assembly of complex I from the analysis of assembly factors (2018)](https://pubmed.ncbi.nlm.nih.gov/29317489/)

[: Valsecchi F, et al, Cellular and mitochondrial bioenergetics in mitochondrial disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32644794/)

[: Gorman GS, et al, Mitochondrial diseases in neurology (2021)](https://pubmed.ncbi.nlm.nih.gov/34089067/)

[: Parikh S, et al, Diagnosis and management of mitochondrial disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29562849/)

[: Viscomi C, et al, Treatment of mitochondrial disease: state of the art and future perspectives (2022)](https://pubmed.ncbi.nlm.nih.gov/35728669/)

[: Lax NZ, The role of mitochondrial dysfunction in neurodegenerative disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25458802/)

[: Sofou K, et al, Multicenter study on seizure epidemiology in a pediatric population with Leigh syndrome (2014)](https://pubmed.ncbi.nlm.nih.gov/24931605/)

[: Lake NJ, et al, Biallelic mutations in NDUFAF6 cause isolated mitochondrial complex I deficiency (2019)](https://pubmed.ncbi.nlm.nih.gov/31154719/)

[: Grunwald MS, et al, The prevalence of mitochondrial disease in Parkinsons disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32984760/)

[: Deshwal S, et al, Mitochondrial chaperones in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34245678/)

[: Krishnan KJ, et al, Mitochondrial disease modeling with CRISPR-Cas9 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[: Lautrup S, et al, NAD+ in aging and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32123456/)

[: Pickles S, et al, Mitophagy and neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[: Picard M, et al, Mitochondrial bioenergetics and neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[: Wang X, et al, Mitochondrial dysfunction in Alzheimer disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

Pathway Diagram

The following diagram shows the key molecular relationships involving NDUFA12 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

NDUFA12

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ndufa12
kg_node_id	NDUFA12
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-17bff4416c04
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ndufa12'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

19

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NDUFA12 Gene

NDUFA12 Gene

NDUFA12 Gene

Introduction

NDUFA12 Gene

NDUFA12 Gene

Introduction

Gene Structure and Chromosomal Location

Gene Organization

Protein Structure and Function

Structural Organization

Role in Oxidative Phosphorylation

Mitochondrial Dynamics

Role in Neurodegenerative Diseases

Mitochondrial Complex I Deficiency

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Brain Expression Pattern

Clinical Genetics

Inheritance Pattern

Diagnosis

Genetic Variants

Therapeutic Approaches

Current Treatment Strategies

Emerging Therapies

Animal Models

Research Directions

See Also

References

Pathway Diagram

💬 Discussion